AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8439216 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 300
Study 8439216 — intervention group
Group type: COMPARATOR
Intervention: Prolonged glucose administration (250-300 g/day)
Number of subjects: 300
Study 3812050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette discrimination task
Number of subjects: 0
Study 3812050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette sweetness ratings
Number of subjects: 0
Study 3812050 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine, tar, and carbon monoxide
Number of subjects: 0
Study 31331582 — intervention group
Group type: EXPERIMENTAL
Intervention: So-Cheong-Ryong-Tang (SCRT)
Number of subjects: 0
Study 31331582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29988125 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 29988125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26596973 — intervention group
Group type: EXPERIMENTAL
Intervention: romiplostim
Number of subjects: 124
Study 26596973 — intervention group
Group type: EXPERIMENTAL
Intervention: eltrombopag
Number of subjects: 124
Study 24879888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-burning exercise
Number of subjects: 96
Study 24879888 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise
Number of subjects: 96
Study 22481647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail lacquer containing ciclopirox 8% applied once weekly
Number of subjects: 41
Study 22481647 — intervention group
Group type: COMPARATOR
Intervention: Nail lacquer containing ciclopirox 8% applied using the traditional regimen (3/2/1)
Number of subjects: 41
Study 20154483 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beclomethasone dipropionate (BDP) administration
Number of subjects: 5
Study 18584525 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiviral induction therapy: amantadine hydrochloride and ribavirin, combined with 6 weeks interferon alfa‐2b (weeks 1‐2: 18 MU/day, weeks 3‐4: 9 MU/day, weeks 5‐6: 6 MU/day), thereafter combined with weekly peginterferon alfa‐2b
Number of subjects: 100
Study 18584525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast responders treated for 24 weeks
Number of subjects: 100
Study 18584525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast responders treated for 48 weeks
Number of subjects: 100
Study 18584525 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-naive patients with HCV RNA <5 IU/mL at week 1 or 2
Number of subjects: 100
Study 18584525 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-naive patients with HCV RNA >or=5 IU/mL at week 16
Number of subjects: 100
Study 18584525 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous non‐responders/relapsers with HCV RNA <5 IU/mL at week 2
Number of subjects: 100
Study 18584525 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous non‐responders/relapsers with HCV RNA >or=5 IU/mL at week 8
Number of subjects: 100
Study 15319016 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 0
Study 15319016 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH tid
Number of subjects: 0
Study 15319016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15319016 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS MPH (during the first year of the open-label study)
Number of subjects: 0
Study 15319016 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS MPH
Number of subjects: 0
Study 15319016 — intervention group
Group type: EXPERIMENTAL
Intervention: History of tics
Number of subjects: 0
Study 11059861 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ciprofloxacin 200 mg/12 h for 7 days (group A)
Number of subjects: 80
Study 11059861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 200 mg/12 h for 2 days followed by oral ciprofloxacin 500 mg/12 h for 5 days (group B)
Number of subjects: 80
Study 9082266 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen
Number of subjects: 90
Study 9082266 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl-droperidol
Number of subjects: 90
Study 8375123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine administration
Number of subjects: 6
Study 8375123 — intervention group
Group type: COMPARATOR
Intervention: Rectal morphine administration
Number of subjects: 6
Study 3532469 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFH (CMF plus homoharringtonine)
Number of subjects: 92
Study 3532469 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, fluorouracil)
Number of subjects: 92
Study 3532469 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 92
Study 31277165 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (3 cycles of combination therapy with carboplatin and nab‐paclitaxel)
Number of subjects: 25
Study 27890714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin Fosfomycin Inhalation System (AFIS) - 300 mg amikacin/120 mg fosfomycin, delivered by aerosol twice daily for 10 days (or to extubation if < 10 days) via the investigational eFlow Inline System.
Number of subjects: 143
Study 27890714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline), delivered by aerosol twice daily for 10 days (or to extubation if < 10 days) via the investigational eFlow Inline System.
Number of subjects: 143
Study 27890714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin Fosfomycin Inhalation System (AFIS)
Number of subjects: 143
Study 27890714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 143
Study 25651955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures
Number of subjects: 126
Study 25651955 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable mesh (Surgisis)
Number of subjects: 126
Study 25651955 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable mesh (Timesh)
Number of subjects: 126
Study 25651955 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 126
Study 25651955 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (recurrence analysis)
Number of subjects: 126
Study 24316218 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill CPET
Number of subjects: 55
Study 24316218 — intervention group
Group type: COMPARATOR
Intervention: Cycle CPET
Number of subjects: 55
Study 23017827 — intervention group
Group type: EXPERIMENTAL
Intervention: REPYFLEC cognitive remediation group training
Number of subjects: 62
Study 23017827 — intervention group
Group type: COMPARATOR
Intervention: Control group (activities without specific objectives and focused on leisure)
Number of subjects: 62
Study 19543195 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS with Cutting-Balloon Angioplasty (CBA)
Number of subjects: 102
Study 19543195 — intervention group
Group type: COMPARATOR
Intervention: Standard CAS
Number of subjects: 102
Study 17292412 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 227
Study 17292412 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 227
Study 17292412 — intervention group
Group type: EXPERIMENTAL
Intervention: NK-stimulatory cytokines (IL-2, IL-12, IL-15)
Number of subjects: 227
Study 17292412 — intervention group
Group type: EXPERIMENTAL
Intervention: Media alone or with IL-2
Number of subjects: 227
Study 15064259 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3 receptor antagonists combined with droperidol
Number of subjects: 3447
Study 15064259 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3 receptor antagonists combined with dexamethasone
Number of subjects: 3447
Study 15064259 — intervention group
Group type: COMPARATOR
Intervention: 5-HT3 receptor antagonists alone
Number of subjects: 3447
Study 11192362 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL (200 mg once daily)
Number of subjects: 3991
Study 9088814 — intervention group
Group type: COMPARATOR
Intervention: Controlled hypotension alone (Group A)
Number of subjects: 30
Study 9088814 — intervention group
Group type: COMPARATOR
Intervention: Haemodilution alone (Group B)
Number of subjects: 30
Study 9088814 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension and haemodilution (Group C)
Number of subjects: 30
Study 8478543 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient telephone surveys
Number of subjects: 501
Study 8478543 — intervention group
Group type: COMPARATOR
Intervention: Traditional surveillance system and monthly physician questionnaires
Number of subjects: 501
Study 3823636 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg body weight; equivalent to approximately 4 cups of coffee)
Number of subjects: 7
Study 3823636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30287240 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (11-17 points)
Number of subjects: 6874
Study 30287240 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (upper third)
Number of subjects: 6874
Study 30287240 — intervention group
Group type: COMPARATOR
Intervention: Low adherence to Mediterranean diet (≤ 7 points)
Number of subjects: 6874
Study 28817223 — intervention group
Group type: COMPARATOR
Intervention: MK-1293
Number of subjects: 185
Study 28817223 — intervention group
Group type: COMPARATOR
Intervention: EU-Lantus
Number of subjects: 185
Study 28817223 — intervention group
Group type: COMPARATOR
Intervention: US-Lantus
Number of subjects: 185
Study 27338460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy-based beverage (DBB)
Number of subjects: 13
Study 27338460 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (CHO)
Number of subjects: 13
Study 27338460 — intervention group
Group type: COMPARATOR
Intervention: Water control (H2O)
Number of subjects: 13
Study 25668387 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based balance training program (postural stability training program using the Biodex Balance System SD)
Number of subjects: 30
Study 25668387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 23936886 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted knowledge translation intervention consisting of interactive education, mentorship through quality circles, and practice-based tools.
Number of subjects: 0
Study 21352575 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartslag Limburg intervention (n = 2356)
Number of subjects: 2356
Study 21352575 — intervention group
Group type: COMPARATOR
Intervention: Reference group (n = 758)
Number of subjects: 2356
Study 18301772 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicable diseases
Number of subjects: 66
Study 18301772 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal, perinatal, and nutritional conditions
Number of subjects: 66
Study 18301772 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-communicable diseases
Number of subjects: 66
Study 18301772 — intervention group
Group type: EXPERIMENTAL
Intervention: Injuries
Number of subjects: 66
Study 17020971 — intervention group
Group type: EXPERIMENTAL
Intervention: TT genotype
Number of subjects: 144
Study 17020971 — intervention group
Group type: EXPERIMENTAL
Intervention: TC genotype
Number of subjects: 144
Study 17020971 — intervention group
Group type: EXPERIMENTAL
Intervention: CC genotype
Number of subjects: 144
Study 17020971 — intervention group
Group type: EXPERIMENTAL
Intervention: ZAP-70 positive CC genotypes
Number of subjects: 144
Study 17020971 — intervention group
Group type: EXPERIMENTAL
Intervention: T-alleles
Number of subjects: 144
Study 14617471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine general anaesthesia with 0.6 mg atropine and 10 mg diazepam premedication
Number of subjects: 295
Study 14617471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine general anaesthesia with 0.6 mg atropine and 50 mg promethazine premedication
Number of subjects: 295
Study 14617471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine general anaesthesia with only 0.6 mg atropine
Number of subjects: 295
Study 14617471 — intervention group
Group type: COMPARATOR
Intervention: Ketamine general anaesthesia
Number of subjects: 295
Study 11035130 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg daily
Number of subjects: 75
Study 11035130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 9173652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypovolemic haemodilution
Number of subjects: 0
Study 9173652 — intervention group
Group type: EXPERIMENTAL
Intervention: Normovolemic haemodilution with Ringer solution
Number of subjects: 0
Study 9173652 — intervention group
Group type: COMPARATOR
Intervention: Normovolemic haemodilution with 6% hydroxyethyl starch
Number of subjects: 0
Study 1405316 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan membranes (hemodialyzed patients)
Number of subjects: 25
Study 1405316 — intervention group
Group type: EXPERIMENTAL
Intervention: Control subjects
Number of subjects: 25
Study 30823952 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoid combined with tiotropium bromide
Number of subjects: 86
Study 30823952 — intervention group
Group type: COMPARATOR
Intervention: Inhaled glucocorticoid
Number of subjects: 86
Study 28044450 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 36
Study 28044450 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg theanine
Number of subjects: 36
Study 28044450 — intervention group
Group type: COMPARATOR
Intervention: 200 mg caffeine + 200 mg theanine
Number of subjects: 36
Study 28044450 — intervention group
Group type: COMPARATOR
Intervention: 0 mg caffeine + 0 mg theanine (placebo)
Number of subjects: 36
Study 25366866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 38
Study 25366866 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 38
Study 25366866 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 38
Study 25366866 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 38
Study 24912486 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 0
Study 24912486 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy (OT)
Number of subjects: 0
Study 21388828 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 1220
Study 21388828 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1220
Study 19687032 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (Group R) - continuous infusion titrated between 3 and 4 ng ml‐1
Number of subjects: 80
Study 19687032 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulphate (Group M) - i.v. bolus of 50 mg kg‐1 followed by a 15 mg kg‐1 h ‐1 continuous infusion
Number of subjects: 80
Study 17490862 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 to 2550 mg daily)
Number of subjects: 80
Study 17490862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17490862 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 80
Study 16270291 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of external heat to the anterior aspect of the knee (heated knee)
Number of subjects: 8
Study 16270291 — intervention group
Group type: COMPARATOR
Intervention: Contralateral knee (control)
Number of subjects: 8
Study 12133054 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer-administered questionnaire
Number of subjects: 930
Study 10210574 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated mTF levels in patients with bladder and prostate malignancy
Number of subjects: 243
Study 10210574 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mTF levels in benign inflammatory groups
Number of subjects: 243
Study 10210574 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated mTF levels
Number of subjects: 243
Study 10210574 — intervention group
Group type: EXPERIMENTAL
Intervention: mTF levels in patients with bladder cancer recurrence
Number of subjects: 243
Study 10210574 — intervention group
Group type: EXPERIMENTAL
Intervention: mTF levels association
Number of subjects: 243
Study 7752590 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary NaCl restriction (5 +/- 3 mmol/day) during KCl deprivation (−67 mmol/day)
Number of subjects: 10
Study 7752590 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary NaCl restriction (5 +/- 3 mmol/day) during KHCO3 deprivation (−64 mmol/day)
Number of subjects: 10
Study 7752590 — intervention group
Group type: EXPERIMENTAL
Intervention: Restoration of KCl to the diets
Number of subjects: 10
Study 7752590 — intervention group
Group type: EXPERIMENTAL
Intervention: Restoration of KHCO3 to the diets
Number of subjects: 10
Study 2097486 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg)
Number of subjects: 80
Study 2097486 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study 2097486 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (300 mg)
Number of subjects: 80
Study 7023166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1,200 mg daily)
Number of subjects: 27
Study 7023166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30612325 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplements for 4 months
Number of subjects: 46
Study 30612325 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplements for 4 months
Number of subjects: 46
Study 26978327 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine ER (3 to 15 mg/day based on body weight)
Number of subjects: 121
Study 26978327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 26978327 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine ER
Number of subjects: 121
Study 25982134 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (30 mg kg(‐1)) with FIBTEM MCF trigger <13 mm (early substitution)
Number of subjects: 49
Study 25982134 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogen concentrate (30 mg kg(‐1)) with FIBTEM MCF trigger <8 mm (conventional)
Number of subjects: 49
Study 25982134 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (30 mg kg(‐1))
Number of subjects: 49
Study 23454226 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-based denture liners
Number of subjects: 30
Study 23454226 — intervention group
Group type: COMPARATOR
Intervention: Control (acrylic resin)
Number of subjects: 30
Study 23454226 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture stomatitis patients with silicone-based denture liners
Number of subjects: 30
Study 20945114 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented intervention
Number of subjects: 845
Study 20945114 — intervention group
Group type: COMPARATOR
Intervention: Basic intervention
Number of subjects: 845
Study 19877063 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide (20 microg/day)
Number of subjects: 428
Study 19877063 — intervention group
Group type: COMPARATOR
Intervention: alendronate (10 mg/day)
Number of subjects: 428
Study 17122617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) with inflow occlusion
Number of subjects: 73
Study 17122617 — intervention group
Group type: COMPARATOR
Intervention: Intermittent clamping (IC)
Number of subjects: 73
Study 17122617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IP and IC)
Number of subjects: 73
Study 14767298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 19
Study 14767298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11778119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (intravenous and epidural)
Number of subjects: 24
Study 11778119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil in combination with local anaesthetics (ropivacaine, bupivacaine)
Number of subjects: 24
Study 11778119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil with adjuvant drugs (clonidine, ketamine, adrenaline)
Number of subjects: 24
Study 11778119 — intervention group
Group type: EXPERIMENTAL
Intervention: Various administration methods (PCA, PCEA, fixed intervals doses, continuous infusion)
Number of subjects: 24
Study 9233591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosphamide, etoposide and epirubicin (IVE) plus G-CSF
Number of subjects: 66
Study 9233591 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide plus G-CSF
Number of subjects: 66
Study 8121964 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (alpha-tocopherol)
Number of subjects: 0
Study 8121964 — intervention group
Group type: COMPARATOR
Intervention: Placebo substitution after Vitamin E treatment
Number of subjects: 0
Study 3117864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (metered-dose inhaler, 2 mg, four times a day, or capsules, 20 mg, four times a day)
Number of subjects: 397
Study 3117864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 29285796 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based treatment (0.3 g/kg body weight)
Number of subjects: 37
Study 29285796 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (15 g for adults, 10 g for children)
Number of subjects: 37
Study 26045533 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental temperature increase by 1 °C
Number of subjects: 2067
Study 26045533 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock genes
Number of subjects: 2067
Study 26045533 — intervention group
Group type: COMPARATOR
Intervention: Environmental temperature
Number of subjects: 2067
Study 25281992 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400mg
Number of subjects: 1065
Study 25281992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1065
Study 25281992 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole once-monthly 50mg
Number of subjects: 1065
Study 23471546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg QD
Number of subjects: 928
Study 23471546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg QD
Number of subjects: 928